ExeVir Bio is developing covid-19 treatments, more specifically a llama-derived nanobody covid-19 therapeutic. To support the clinical trials of its second-generation medicine, the Belgian biotech has now secured a €25M venture loan from the European Investment Bank.
Quinz has assisted ExeVir in negotiating the terms of the venture debt with the EIB. Over the past years, Quinz has also assisted ExeVir Bio with respect to several financing rounds for a total sum of €42M, including from investors such as Fund+, UCB, V-Bio Ventures, SRIW, Noshaq and several family offices. In addition, Quinz’ life sciences team is actively assisting ExeVir Bio with respect to regulatory matters.
The Quinz team was led by Klaas Thibaut and Wout Hooyberghs.
